In the six decades of Cuban medical collaboration abroad, its health personnel have assisted 1.988 billion people in the world, almost a third of mankind, said Dr. Jorge Delgado Bustillo, director of the Central Unit for Medical Cooperation (UCCM).
Industrial production has begun of Cuba’s candidate vaccines Soberana 02 and Abdala (CIGB-66), two of the four developed on the island to combat COVID-19, with progress advancing at BioCubaFarma facilities.
The days ahead do not seem favorable for the prevention and control of COVID-19. At least that is what short-term forecasts predict. Confirmed cases will increase; recovered patients will also increase, but on a smaller scale than the number of new patients.
Cuban scientists announced the production of the first batch of 150,000 Soberana 02 vaccines against the SARS-CoV-2 coronavirus, which causes the COVID-19 disease that has already killed more than 2.3 million people worldwide.
